There is a second layer of EGFR
mutations that are not the classic immune EGFR
mutations, such as exon 19 deletions. We do not have good drugs for those—particularly EGFR
duplications for which currently we are using afatinib (Gilotrif). For patients with EGFR
insertions, we do not have good [agents]. Those patients would benefit from any available clinical trials.
The last couple of years have significantly changed lung cancer treatment with the explosion of immunotherapy and targeted agents. What’s next?
There is room for significant optimism in the current lung cancer therapeutic landscape. Newer drugs are showing improvements to PFS over older, existing drugs, which is a dramatic improvement. We are now seeing PFS pushing 2 years, and overall survival is now pushing 3 to 5 years. The lung cancer landscape has dramatically changed over the last decade or so and we are still scratching the surface. There are new data to come and more studies to be conducted, which will increase our understanding to optimally treat patients with advanced NSCLC.